IN2012DN02103A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02103A IN2012DN02103A IN2103DEN2012A IN2012DN02103A IN 2012DN02103 A IN2012DN02103 A IN 2012DN02103A IN 2103DEN2012 A IN2103DEN2012 A IN 2103DEN2012A IN 2012DN02103 A IN2012DN02103 A IN 2012DN02103A
- Authority
- IN
- India
- Prior art keywords
- compounds
- maintenance
- treatment
- conditions
- induction
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000006698 induction Effects 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 238000012423 maintenance Methods 0.000 abstract 2
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 229940122381 Oxytocin receptor agonist Drugs 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000037805 labour Diseases 0.000 abstract 1
- 230000006651 lactation Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of, inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification:
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24432709P | 2009-09-21 | 2009-09-21 | |
| PCT/US2010/049714 WO2011035330A2 (en) | 2009-09-21 | 2010-09-21 | Oxytocin receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02103A true IN2012DN02103A (en) | 2015-08-21 |
Family
ID=43629442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2103DEN2012 IN2012DN02103A (en) | 2009-09-21 | 2010-09-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8748564B2 (en) |
| EP (1) | EP2491052A2 (en) |
| JP (1) | JP5750443B2 (en) |
| KR (1) | KR20120093840A (en) |
| CN (1) | CN102656183B (en) |
| AR (1) | AR078304A1 (en) |
| AU (1) | AU2010295294B2 (en) |
| BR (1) | BR112012006185A2 (en) |
| CA (1) | CA2774593C (en) |
| IL (1) | IL218649A (en) |
| IN (1) | IN2012DN02103A (en) |
| MX (1) | MX2012003208A (en) |
| NZ (1) | NZ598579A (en) |
| RU (1) | RU2539692C2 (en) |
| SA (1) | SA110310710B1 (en) |
| TW (1) | TWI463990B (en) |
| WO (1) | WO2011035330A2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| JP6067878B2 (en) * | 2012-12-21 | 2017-01-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Peptides as oxytocin agonists |
| AU2015270723A1 (en) * | 2014-06-03 | 2016-11-17 | F. Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| CR20160562A (en) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | PEPTIDES AS OXYCHOCINE AGONISTS |
| US10265372B2 (en) | 2014-08-12 | 2019-04-23 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
| HRP20240166T1 (en) | 2014-09-19 | 2024-04-26 | Ferring B.V. | Method of treating prader-willi syndrome |
| MX392636B (en) | 2014-10-31 | 2025-03-24 | Glaxosmithkline Ip Dev Ltd | POWDER FORMULATION. |
| CA3001057A1 (en) * | 2015-10-06 | 2017-04-13 | Ferring B.V. | New methods for making barusiban and its intermediates |
| CN106967155B (en) * | 2017-03-17 | 2018-05-15 | 兰州凯博药业股份有限公司 | A kind of method of peptide synthesis in liquid phase oxytocin |
| US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| US11414459B2 (en) | 2017-09-28 | 2022-08-16 | Kinoxis Therapeutics Pty Ltd | Metabolite inspired selective oxytocin receptor agonists |
| US12303498B2 (en) | 2018-03-23 | 2025-05-20 | Cytoo | ALK5 inhibitors as skeletal muscle hypertrophy inducers |
| AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| KR20210062638A (en) | 2018-09-20 | 2021-05-31 | 레보 테라퓨틱스 인코포레이티드 | Stable intranasal formulation of carbetosine |
| CN113950331A (en) * | 2019-11-04 | 2022-01-18 | 辉凌公司 | Intranasal administration of meloxicam for improving lactation |
| HRP20250303T1 (en) | 2021-03-26 | 2025-05-09 | Centre Hospitalier Universitaire De Toulouse | Treatment of dysphagia |
| WO2023118303A1 (en) | 2021-12-21 | 2023-06-29 | Universitaet Wien | Highly stable oxytocin derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS194980B1 (en) * | 1976-07-16 | 1979-12-31 | Joseph H Cort | Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle |
| SE430885B (en) * | 1980-03-24 | 1983-12-19 | Ferring Ab | OXYTOCIN DERIVATIVES |
| CS216722B1 (en) * | 1980-06-24 | 1982-11-26 | Michal Lebl | Oxytocine analogues and method of making the same |
| US4483794A (en) * | 1983-05-10 | 1984-11-20 | Ceskoslovenska Akademie Ved | Analogs of neurohypophysial hormones |
| SE9604341D0 (en) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| EP1351702B1 (en) * | 2000-12-08 | 2015-03-04 | Bioprovar Corporation | Trem-1 splice variant for use in modifying immune responses |
| WO2003072597A1 (en) | 2002-02-27 | 2003-09-04 | Ferring Bv | Intermediates and methods for making heptapeptide oxytocin analogues |
| KR101194586B1 (en) * | 2006-02-10 | 2012-10-25 | 훼링 비.브이. | Novel compounds |
-
2010
- 2010-09-08 TW TW099130296A patent/TWI463990B/en not_active IP Right Cessation
- 2010-09-20 SA SA110310710A patent/SA110310710B1/en unknown
- 2010-09-21 EP EP10777131A patent/EP2491052A2/en not_active Withdrawn
- 2010-09-21 CA CA2774593A patent/CA2774593C/en not_active Expired - Fee Related
- 2010-09-21 WO PCT/US2010/049714 patent/WO2011035330A2/en not_active Ceased
- 2010-09-21 AU AU2010295294A patent/AU2010295294B2/en not_active Ceased
- 2010-09-21 MX MX2012003208A patent/MX2012003208A/en active IP Right Grant
- 2010-09-21 KR KR1020127006787A patent/KR20120093840A/en not_active Abandoned
- 2010-09-21 AR ARP100103440A patent/AR078304A1/en unknown
- 2010-09-21 NZ NZ598579A patent/NZ598579A/en not_active IP Right Cessation
- 2010-09-21 US US13/496,269 patent/US8748564B2/en not_active Expired - Fee Related
- 2010-09-21 BR BR112012006185A patent/BR112012006185A2/en not_active IP Right Cessation
- 2010-09-21 JP JP2012529981A patent/JP5750443B2/en not_active Expired - Fee Related
- 2010-09-21 IN IN2103DEN2012 patent/IN2012DN02103A/en unknown
- 2010-09-21 CN CN201080041788.0A patent/CN102656183B/en not_active Expired - Fee Related
- 2010-09-21 RU RU2012110349/04A patent/RU2539692C2/en not_active IP Right Cessation
-
2012
- 2012-03-15 IL IL218649A patent/IL218649A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2491052A2 (en) | 2012-08-29 |
| MX2012003208A (en) | 2012-05-29 |
| WO2011035330A3 (en) | 2011-05-19 |
| SA110310710B1 (en) | 2015-01-05 |
| CA2774593C (en) | 2016-12-06 |
| RU2012110349A (en) | 2013-10-27 |
| IL218649A0 (en) | 2012-05-31 |
| CN102656183B (en) | 2016-03-30 |
| US20120214733A1 (en) | 2012-08-23 |
| NZ598579A (en) | 2014-02-28 |
| TWI463990B (en) | 2014-12-11 |
| AU2010295294A8 (en) | 2012-05-31 |
| JP5750443B2 (en) | 2015-07-22 |
| KR20120093840A (en) | 2012-08-23 |
| CN102656183A (en) | 2012-09-05 |
| WO2011035330A4 (en) | 2011-07-07 |
| IL218649A (en) | 2016-11-30 |
| RU2539692C2 (en) | 2015-01-27 |
| US8748564B2 (en) | 2014-06-10 |
| BR112012006185A2 (en) | 2016-05-31 |
| JP2013505269A (en) | 2013-02-14 |
| WO2011035330A2 (en) | 2011-03-24 |
| AR078304A1 (en) | 2011-10-26 |
| CA2774593A1 (en) | 2011-03-24 |
| TW201114434A (en) | 2011-05-01 |
| AU2010295294A1 (en) | 2012-03-29 |
| AU2010295294B2 (en) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02103A (en) | ||
| PH12015501289B1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| EA031157B9 (en) | Orally administered corticosteroid composition | |
| MX2014002394A (en) | Biphenylcarboxamides as rock kinase inhibitors. | |
| EA201070549A1 (en) | LH LIQUID COMPOSITIONS | |
| MX342161B (en) | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders. | |
| PH12012500622A1 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
| MY175854A (en) | Novel quinolone derivatives | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| TN2012000534A1 (en) | Pyrazole compounds as sigma receptor inhibitors | |
| IN2014MN00697A (en) | ||
| IN2014CN03854A (en) | ||
| MX2014000142A (en) | Use of anti-cd83 agonist antibodies for treating autoimmune diseases. | |
| WO2013175377A3 (en) | Compositions and methods for treatment of mucositis | |
| IN2014CN02364A (en) | ||
| MX2011012669A (en) | Novel glucocorticoid receptor agonists. | |
| GEP20156231B (en) | Agomelatine hydrochloride hydrate and preparation there of | |
| IN2013DN02555A (en) | ||
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| GEP20156232B (en) | Agomelatine hydrochloride hydrate and preparation thereof | |
| HK1174928A (en) | Oxytocin receptor agonists | |
| IN2014KN00847A (en) | ||
| MX2015006871A (en) | Crystallization process of tricyclic indole derivatives. | |
| FI20106293A0 (en) | New pharmaceutical compositions |